Kimberly Blumenthal, MD, MSc is an Allergist/Immunologist and clinical researcher at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. She is the Director of Research in the Center for Drug and Vaccine Allergy. Her research interests are drug and vaccine allergy which has been funded by the National Institute of Health, Agency for Healthcare Research and Quality, and foundations, including the American Academy of Allergy, Asthma, and Immunology Foundation and CRICO, the risk management foundation of Harvard Medical School. She is internationally recognized for identifying the morbidity and mortality associated with unverified penicillin allergies and creating innovative approaches to the evaluation of penicillin and cephalosporin antibiotic allergies in diverse patient settings. She has authored more than 170 peer-reviewed publications including leading high-impact manuscripts to publication in journals such as NEJM, Lancet, JAMA, and the BMJ.
Clinical Interests:
Treats:
Languages:
Mass General Medicine: Allergy & Clinical Immunology Unit
55 Fruit St.
Yawkey 4B
Boston, MA 02114
Phone: 617-726-3850
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Blumenthal's clinical research laboratory is funded by the National Institutes of Health, the American Academy of Allergy, Asthma, and Immunology, CRICO, and the MGH Executive Committee on Research.. She has authored or co-authored over 50 peer-reviewed publications related to improving the care of patients with drug allergies. Dr. Blumenthal is Principal Investigator of the United States Drug Allergy Registry (USDAR), the first national prospective cohort of patients who receive drug allergy evaluations.
Dr. Blumenthal performs epidemiology, informatics, outcomes and cost-effectiveness research in the field of drug allergy. Her past research evaluated both true drug hypersensitivity and the clinical impact of over-reported drug allergies on patients and healthcare systems, and includes over 70 peer-reviewed manuscripts.
As part of her post-doctoral research, she designed, implemented and evaluated a hospital-wide guideline for antibiotic prescribing for patients with a reported β-lactam antibiotic allergy at Mass General. After successfully demonstrating the guideline’s safety, feasibility, and positive impact on antibiotic stewardship at two institutions, she led the implementation of this guideline throughout Mass General Brigham hospitals.
Dr. Blumenthal is Principal investigator of the United States Drug Allergy Registry (usdar.massgeneral.org), a longitudinal prospective cohort of patients assessed for possible drug allergy, including a possible allergy to penicillin antibiotics.
